补肾温肺合剂治疗小鼠支气管哮喘的作用及机制研究

Effect and Mechanism of BuShen WenFei Mixture on Treatment of Bronchial Asthma in Mice

目的研究补肾温肺合剂对哮喘小鼠的治疗作用及机制。方法 60只昆明系小鼠随机分为6组,即对照组、模型组、阳性对照组(地塞米松,2mg·kg^(-1))、补肾温肺合剂高(36g·kg^(-1))、中(18g·kg^(-1))、低剂量组(9g·kg^(-1)),每组10只。通过卵蛋白(OVA)先腹腔注射,后雾化吸入激发的方式建立哮喘小鼠模型,采用酶联免疫法(ELISA)检测支气管肺泡灌洗液(BALF)中IL-4、IL-13和IFN-γ水平,并通过Diff-Quick染色法对BALF中各类炎性细胞进行计数。结果与对照组比较,模型组BALF中各类炎性细胞数量升高显著(P<0.01,P<0.05),IL-4和IL-13的含量明显升高(P<0.01),IFN-γ含量显著降低(P<0.01)。与模型组比较,各治疗组BALF中炎性细胞数量降低明显(P<0.01,P<0.05),补肾温肺合剂低剂量组对淋巴细胞和中性粒细胞作用不显著(P>0.05)。与模型组比较,各治疗组BALF中IL-13和IL-4含量均降低,IFN-γ含量均升高。除补肾温肺合剂低剂量组IL-4和IFN-γ差异无统计学意义(P>0.05)外,各治疗组差异均有统计学意义(P<0.01,P<0.05)。结论补肾温肺合剂可能通过调节IL-4、IL-13和IFN-γ途径治疗支气管哮喘。

OBJECTIVE To study the therapeutic effect and mechanism of BuShen WenFei mixture(BSWFM)on asthmatic mice.METHODS 60 KM mice were randomLly divided into the control group,the model group,the positive control group(dexamethasone,2 mg·kg^-1),the high,medium and low dose BSWFM groups,10 in each group.Asthma model was established by intraperitoneal injection of ovalbumin(OVA)and aerosol inhalation.Enzyme-linked immunosorbent assay(ELISA)was used to detect levels of IL-4,IL-13 and IFN-γin bronchoalveolar lavage fluid(BALF).All kinds of inflammatory cells in BALF were counted by Diff-Quick staining.RESULTS Compared with the normal group,the number of inflammatory cells in model group BALF increased significantly(P<0.01,P<0.05),the content of IL-4 and IL-13 increased significantly(P<0.01),the content of IFN-γwas significantly reduced(P<0.01).Compared with the model group,the number of inflammatory cells in the BALF of each treatment group decreased obviously(P<0.01,P<0.05).BSWFM Low dose group had no significant effect on lymphocytes and neutrophils(P>0.05).Compared with the model group,the content of IL-13 and IL-4 in all the treatment groups decreased in BALF,the content of IFN-γwas increased.Except for the difference of IL-4 and IFN-γin the BSWFM low dose group(P>0.05),the differences in the treatment groups were statistically significant(P<0.01,P<0.05).CONCLUSION The BSWFM may modulate IL-4,IL-13 and IFN-γpathways in the treatment of bronchial asthma.